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Only 2 neonates with transplacentally or perinatally 
acquired (congenital) babesiosis have been reported. We 
describe a probable third congenital case of babesiosis in a 
26-day-old infant; transmission was determined on the ba-
sis of a blood smear from the infant (15% parasitemia) and 
serologic results from the infant and mother.
V
ictor Babes ﬁ  rst described the pathogen of babesiosis 
in 1888 (1). Babesiosis is a tick-borne malaria-like ill-
ness transmitted by the same Ixodes spp. ticks that transmit 
Borrelia burgdorferi (2). It is endemic to the northeastern 
and northwestern United States and also occurs in Europe 
and parts of Asia. Babesiosis is an intraerythrocytic para-
sitic infection that ranges from subclinical to severe (possi-
bly fatal) disease with fever, thrombocytopenia, hemolytic 
anemia, and hyperbilirubinemia. Appropriate antimicrobial 
drug therapy, transfusion, and exchange transfusion remain 
the mainstays of treatment.
Babesiosis occurs rarely among neonates, although it 
is gaining increasing attention as an emerging tick-borne 
zoonosis. In 1987, Esernio-Jenssen et al. (3) reported an 
apparent case of transplacentally or perinatally transmitted 
congenital babesiosis. In 1997, New et al. (4) reported an-
other case. We describe a third case of probable congenital 
babesiosis in a 26-day-old infant with 15% parasitemia. 
She was treated successfully with atovaquone (Mepron; 
GlaxoSmithKline, Research Triangle Park, NC, USA) and 
azithromycin (Zithromax; Pﬁ  zer, New York, NY, USA). 
 The Case 
A 26-day-old, 8-pound, full-term infant girl was trans-
ferred to Saint Peter’s University Hospital for evaluation 
of fever and hyperbilirubinemia. For 1 week, she was not 
feeding well and was gagging and irritable. On the day of 
admission, her mother noted fever and yellow eyes. The 
mother (a migrant crop worker) reported having had an un-
eventful pregnancy, labor, and delivery, except for having 
been bitten by 2 ticks at 8 months’ gestation while picking 
crops in New Jersey. She did not seek treatment. The moth-
er had not traveled elsewhere in the United States during 
her pregnancy. Knowledge about earlier travel to Babesia-
endemic areas would have been helpful in understanding 
the mother’s infection, but this information was unavail-
able. The infant had no history of tick exposure; she had 
been outdoors only for visits to the pediatrician. 
Physical examination showed an alert but pale infant 
weighing 4.4 kg; her temperature was 101.8°F (38.7°C), 
pulse rate 160/min, respiratory rate 36/min, blood pressure 
90/40 mm Hg, and oxygen saturation 99% while breath-
ing room air. Her conjunctivae were icteric. Her liver and 
spleen were palpable 4 cm and 5 cm below their respective 
costal margins. No hemorrhagic lesions or tick bites were 
noted. The rest of her physical examination ﬁ  ndings were 
unremarkable except for a diaper rash. 
Initial laboratory ﬁ  ndings included a hemoglobin level 
of 8.8 g/dL (indices within normal limits); leukocyte count 
of 9.0/mm3 with 3% bands, 18% neutrophils, 72% lympho-
cytes, 7% monocytes; and platelet count of 34,000/mm3. 
Blood chemistry concentrations included total and indirect 
bilirubin 5.9 mg/dL (reference range 0.1–1.2 mg/dL); ala-
nine aminotransferase 18 IU/L; aspartate aminotransferase 
53 IU/L; alkaline phosphatase 108 IU/L; blood urea nitro-
gen 6 mg/dL; creatinine 0.3 mg/dL; and C-reactive protein 
54 mg/dL (reference range 1.0–10.0 mg/dL). Peripheral 
blood smear demonstrated evidence of hemolysis and was 
consistent with Babesia microti infection (although B. 
duncani is indistinguishable from B. microti on peripheral 
smear) and ≈15% parasitemia (Figure).
Subsequently, the infant’s lactate dehydrogenase con-
centration was found to be 1,912 IU/L (reference range 
313–618 IU/L) and later rose to 2,535 IU/L (Table 1). The 
infant’s Babesia immunoglobulin (Ig) G and IgM titers by 
immunoﬂ  uorescent antibody (IFA), which are genus spe-
ciﬁ  c but not species speciﬁ  c, were 256 (reference <16) and 
40 (reference <20), respectively (both tests were performed 
by Quest Diagnostics–Nichols Institute, Chantilly, VA, 
USA). Lyme IgG Western blot plus 2 Lyme IgM West-
ern blots, performed early during hospitalization and just 
before discharge, were negative. The mother’s peripheral 
blood smear did not show any parasites, but her Babesia 
IgG and IgM titers by IFA were >1,024 and 80, respec-
tively, and her Lyme serology was positive. The mother 
refused additional testing. Despite the variability in sensi-
tivity and speciﬁ  city of commercially available serologic 
tests (particularly the IFA for Babesia IgM), Babesia sero-
logic results were not conﬁ  rmed at a reference laboratory. 
Species-speciﬁ  c PCR was not performed. 
 After concluding that this infant had probable con-
genital babesiosis, we began treating her with oral atova-
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quone (40 mg/kg/d) in 2 divided doses and azithromycin 
(12 mg/kg/d) once per day. The infant received 1 transfu-
sion with packed red blood cells on hospital day 3 because 
of continued hemolysis, but she did not require exchange 
transfusion despite having a high initial parasite count. The 
infant’s parasitemia decreased rapidly, and she responded 
well to treatment (Table 1). She was discharged after 8 
days and was to complete a 10-day course of atovaquone 
and azithromycin (which were well tolerated); she was sub-
sequently lost to follow-up.
Conclusions 
Of 10 cases of babesiosis in neonates that have been 
reviewed (5), 2 were congenital (3,4), 2 were transmitted 
by a tick bite (6), and 6 were associated with transfusions 
(5,7–9). The 2 congenital cases (3,4) are compared to our 
probable congenital case (Table 2). All 10 of the affected 
neonates were reported to have <9% parasitemia (5). The 
illness ranged from no symptoms in 2 infants transfused 
with contaminated blood (8) to symptomatic disease (as in 
our infant) with fever and hepatosplenomegaly in 5 of 7 
(71%), hemolytic anemia in 8 of 10 (80%), indirect hyper-
bilirubinemia in 4 of 5 (80%), and thrombocytopenia in 7 
of 9 (78%) (5). Five of 8 (63%) patients required eryth-
rocyte transfusion (5). The infant we describe had all of 
these manifestations as well as a higher parasite count than 
described previously (5). Clearly, the spectrum of neonatal 
babesiosis is variable and must be more fully elucidated, as 
must determinants of the illness’s clinical course and para-
site clearance. In neonates, the degree of parasitemia may 
not parallel the severity of the babesiosis.
The combination of quinine sulfate and clindamycin 
hydrochloride for treatment of a newborn with transfusion-
associated babesiosis was described in 1982 and subse-
quently became the ﬁ  rst accepted treatment (7). A combi-
nation of azithromycin with atovaquone for 7 to 10 days 
has emerged as an alternative regimen (8,10–11), having 
been used successfully in 2 neonates (8,10) and several 
adults (11) in whom it appears to be safe and effective. 
Finally, the addition of azithromycin or atovaquone to the 
clindamycin hydrochloride plus quinine sulfate regimen 
has been proposed (2,8), particularly if parasitemia is slow 
to resolve.  
Recently, our understanding of babesiosis and the 
methods of testing for it have improved dramatically. Be-
cause babesiosis (and congenital babesiosis) is an emerging 
tick-borne zoonosis, it is worthwhile to review the state-of-
the-art approach to its diagnosis in the context of the limita-
tions to diagnosis inherent in this particular case, including 
its retrospective nature, the mother’s lack of insurance and 
resultant unwillingness to undergo any additional labora-
tory testing, and the loss to follow-up of the infant and her 
migrant family. 
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Figure. Giemsa-stained (A) and Wright-stained (B) peripheral blood 
smear from a newborn with probable Babesia microti infection. 
Parasitemia was estimated in this newborn at ≈15% based on 
the number of parasites per 200 leukocytes counted. The smear 
demonstrated thrombocytopenia and parasites of variable size and 
morphologic appearance and an absence of pigment. Magniﬁ  cation 
×1,000Diagnosis of congenital babesiosis requires deﬁ  nitive 
evidence of babesiosis, including evidence from reference 
laboratory species-speciﬁ  c IFA testing, PCR conﬁ  rma-
tion, and evidence from reference laboratory evaluation 
of peripheral blood smears, particularly blood smears with 
high parasitemia (necessary because of the numerous spe-
cies of Babesia endemic to the United States, including 
B. microti, B. divergens–like, B. duncani, MO-1, CA-1, 
and WA-1). Accurate diagnosis also requires collection of 
extensive epidemiologic information about patients with 
suspected infections, including their recent and remote 
travel history, exposure to ticks, transfusion or transplant. 
Follow-up for recrudescence is important, particularly for 
the immunocompromised patient. Our report of a prob-
able third case of congenital babesiosis illustrates the 
variability in the manifestations and clinical course of the 
illness, suggesting a need for improvement in how the dis-
ease is recognized and for evaluation of current treatment 
modalities.  
Dr Sethi is a pediatric resident at The Children’s Hospital at 
Monmouth Medical Center in Long Branch, New Jersey. She is 
interested in pediatric cardiology.
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Table 1. Clinical and laboratory data for infant with probable congenital babesiosis* 
Day of hospitalization 
Clinical/laboratory data  1 234 5 6 7 8
Maximum daily temperature, ºF  102.7 101.9 100.6 98.0 98.8 99.6 99.4 98.8
Hepatomegaly, cm below costal 
margin
4 4 4 5 Stable Stable Smaller Smaller
Splenomegaly, cm below costal 
margin
5 5 5 5 Stable Stable Smaller Smaller
Lowest daily hemoglobin level, g/dL  8.8 8.1 7.0† 9.8 8.6 7.4 8.5 9.6
Lowest daily platelet count, 10
3/mm
3 34 30 23 34 45 112 185 340
Parasitemia, %  15.2 Present‡ Present‡ 2 <1 NA 0N A
Highest daily total bilirubin level, 
mg/dL
5.9§ NA 3.6 3.9 2.7 2.1 1.7 1.3
Highest daily lactate dehydrogenase 
level, IU/L 
NA NA 1,912¶ 2,481 2,535 2,286 2,239 1,566
Highest daily C-reactive protein level, 
mg/dL
54# NA 130 82 62 39 NA NA
Treatment CRO,
ATO, AZI
CRO,
ATO, AZI
CRO, ATO, 
AZI, PRBC
CRO,
ATO, AZI
CRO,
ATO, AZI
CRO,
ATO, AZI 
CRO,
ATO, AZI
CRO,
ATO, AZI
*NA, not assessed; CRO, ceftriaxone sodium; ATO, atovaquone; AZI, azithromycin; PRBC, packed red blood cells. 
†Before PRBC transfusion. 
‡Not quantified. 
§Reference range 0.1–1.2 mg/dL. 
¶Reference range 313–618 IU/L. 
#Reference range 1.0–10.0 mg/dL. 
Table 2. Selected clinical data from the first 2 reported cases of congenital babesiosis (3,4) and the probable case described in this 
article*
Clinical data  Reference case 1   Reference case 2   Present case 
Infant’s age at time of illness  30 d  5 wk  26 d 
Time of maternal tick bite before delivery  1 wk  7 wk  4 wk 
Serologic test results for Babesia spp.
 Mother  Pos Pos Pos
Infant Pos Pos Pos
Clinical findings  Fever, irritability, pallor, 
hepatosplenomegaly 
Lethargy, poor feeding, 
pallor 
Fever, poor feeding, irritability, 
pallor, scleral icterus, 
hepatosplenomegaly 
Parasitemia, %  5 4.4 15
Treatment (duration)  Ampicillin and gentamicin 
(3 d); clindamycin and 
quinine sulfate (10 d) 
Clindamycin and quinine 
sulfate (12 d); 
azithromycin (10 d) 
Ceftriaxone (8 d); atovaquone 
and azithromycin (10 d) 
*All infants’ history of tick exposure was negative, and all recovered.  Probable Congenital Babesiosis
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